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The advent of effective combination antiretroviral therapy (ART) in 1996 resulted in fewer patients experiencing clinical events, so that some prognostic analyses of individual cohort studies of human immunodeficiency virus-infected individuals had low statistical power. Because of this, the Antiretroviral Therapy Cohort Collaboration (ART-CC) of HIV cohort studies in Europe and North America was established in 2000, with the aim of studying the prognosis for clinical events in acquired immune deficiency syndrome (AIDS) and the mortality of adult patients treated for HIV-1 infection. In 2002, the ART-CC collected data on more than 12,000 patients in 13 cohorts who had begun combination ART between 1995 and 2001. Subsequent updates took place in 2004, 2006, 2008, and 2010 . The ART-CC data base now includes data on more than 70 000 patients participating in 19 cohorts who began treatment before the end of 2009. Data are collected on patient demographics (e.g. sex, age, assumed transmission group, race/ethnicity, geographical origin), HIV biomarkers (e.g. CD4 cell count, plasma viral load of HIV-1), ART regimen, dates and types of AIDS events, and dates and causes of death. In recent years, additional data on co-infections such as hepatitis C; risk factors such as smoking, alcohol and drug use; non-HIV biomarkers such as haemoglobin and liver enzymes; and adherence to ART have been collected whenever available. The data remain the property of the contributing cohorts, whose representatives manage the ART-CC via the steering committee of the Collaboration. External collaboration is welcomed. Details of contacts are given on the ART-CC website (www.art-cohort-collaboration.org).
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Why was the cohort set up?
The Antiretroviral Therapy Cohort Collaboration (ART-CC) was established in 2000 to study the prognosis for adult patients treated for human immunodeficiency virus-1 (HIV-1) infection in Europe and North America. The widespread use since 1996 of combination antiretroviral therapy (ART) has substantially improved the prognosis for HIV-positive patients as compared with those treated with previously available drug regimens of nucleoside reverse transcriptase inhibitors (NRTIs), either in the form of monotherapy with zidovudine or as dual therapy with a second NRTI. 1 The substantial reductions in the number of events and deaths related to acquired immune deficiency syndrome (AIDS) following the introduction of combination ART meant that modelling of prognosis among different patient groups and according to different prognostic factors often required larger numbers of patients than were available in individual cohorts at that time. Therefore, the important task of defining prognosis and prognostic factors in the era of combination ART required several cohorts to contribute data to a collaborative data base. The prognosis for patients starting treatment with combination ART, defined as a combination of at least three drugs belonging to two different classes of drugs, depends on their prior exposure to NRTI monotherapy or dual therapy, because the development of resistance to NRTI drugs as a result of incomplete viral suppression meant that 'treatment-naive' patients who had not previously been treated when they began triple ART had a better prognosis. Because future patients would begin treatment with triple ART rather than with NRTIs, treating physicians and their patients needed to know the prognosis for treatment-naïve patients starting combination ART according to their demographic characteristics, disease stage, and treatment options. The ART-CC was able to address this key clinical question and thereby improve care for HIV-positive patients.
The co-ordinating centre of the ART-CC was established in the Department of Social Medicine (now the School of Social and Community Medicine) of the University of Bristol, UK. An annual international workshop for researchers working with observational cohorts of HIV-positive patients had been set up in 1997, under the sponsorship of the pharmaceutical company GlaxoSmithKline. At the fourth such workshop, held in 2000 in Marbella, 16 cohorts, in Europe and North America, were approached, and 13 agreed to participate in the collaboration. The ART-CC Steering Committee consists of the Principal Investigator, a representative from each cohort, the co-ordinating team and representatives of patient groups. GlaxoSmithKline funded the first 6 months of the study, and it has since been funded by the UK Medical Research Council together with the fund providers for the contributing cohorts (see Appendix). The aim of the ART-CC, as specified in its detailed Principles of Collaboration, is 'to examine the prognosis of HIV-infected, antiretroviral drug-naïve patients starting combination ART, with a focus on questions that cannot be fully addressed in analyses of data from individual cohorts. In particular, analyses will focus on prognosis of major clinical events (particularly AIDS, AIDS-defining conditions, and all-cause and cause-specific mortality).'
Which cohorts contribute to the collaboration?
The ART-CC is a collaboration of HIV cohort studies in Europe and North America. Table 1 lists the cohorts that have contributed data to the ART-CC. Prospective cohort studies are eligible to participate if they have enrolled at least 100 HIV-1-positive patients aged 16 years or older who have not previously received antiretroviral treatment, who began ART with a combination of at least three antiretroviral drugs after 1996, and who have been followed for a median of at least 1 year after the initiation of ART. Patients are eligible only if they have had at least one measurement of their CD4 cell count and plasma viral load of HIV-1 RNA within 3 months before starting ART. All cohorts have been approved by local ethics committees or institutional review boards, use standardised methods of data collection, and schedule follow-up visits at least once every 6 months for their patients.
Who are the participants in the cohorts?
Each cohort in the ART-CC recruits patients in different ways, and the cohorts therefore differ in how (continued)
COHORT PROFILE: ART-CC What has been measured?
The variables collected at each update of the ART-CC data set have become more extensive over the years and are listed in Table 2 . The first data set included only basic demographic, laboratory, and clinical variables at the beginning of a patients ART and at 6 months after the beginning of ART. In contrast, the most recent update collected comprehensive longitudinal data for laboratory values (including both prognostic markers in HIV infection such as CD4 cells and viral load, and non-HIV-specific biomarkers such as haemoglobin and creatinine), start and stop dates of antiretroviral drugs used during the observation period and the reasons for changes in a drug regimen, and data on causes of death. A panel of experts has retrospectively validated causes of death in ART-CC, using the CoDe system (http://www.cphiv.dk/CoDe/ tabid/55/Default.aspx). Table 3 shows baseline characteristics of patients in each of the 19 ART-CC cohorts that supplied data for the 2010 update. The ANRS C04 FHDH cohort, which recruits patients from most regions of France, contributes the largest number of patients. The cohorts are heterogeneous in nature and outcomes. 3 Reported percentages of patients who have died vary from 1.4% in the Frankfurt cohort to 19% in the HOMER cohort, which recruited a large number of injectiondrug users (IDUs). The proportion of female participants also varies greatly among cohorts, from 1.6% in HAVACS (a cohort of US military veterans) to 33% in FHDH (which has a large proportion of immigrants from sub-Saharan Africa).
What is the extent of attrition?
Overall rates of loss to follow-up in the different AST-CC cohorts has ranged from 2%-18%, depending on opportunities for access to care outside the contributing centres, and cohorts' ability to track patient transfers and pursue patients who miss appointments. Thus, for example, losses to follow-up in the Royal Free cohort are partly due to patients' attending alternative clinics in London. In France, IDUs and immigrants, and patients with lower CD4 cell counts and higher viral loads, were more likely to be lost to follow-up. In contrast, patients in Switzerland with higher CD4 cell counts were more likely to be lost to follow up.
What are the major findings to date?
Prognosis from the beginning of antiretroviral therapy and after accounting for response to therapy Our first paper on the prognosis for HIV-1-infected patients from beginning of ART was published in 2002. 4 This and several other papers from the ART-CC have been cited in treatment guidelines. [5] [6] [7] We showed that the CD4 cell count at which individuals began ART strongly predicted disease progression. A higher viral load, older age, infection via injection-drug use, and a diagnosis of AIDS before the initiation of treatment were also predictors of poorer outcome. The probability of death within 3 years after the beginning of treatment ranged from 0.8%-43%, depending on these risk factors. The prognostic modelling methodology 8 has been used by several other collaborations, 9.10 and the ART-CC prognostic model has been validated with data from the CASCADE collaboration. 11 Further work examined the way in which prognosis depends on the initial response to ART. 12 Viral load and CD4 cell count at 6 months strongly predicted subsequent survival, whereas the values measured at the beginning of treatment no longer predicted survival after accounting for the 6 month measurements.
Analyses were updated in 2007 to include new patients who began ART up to 2003 and a longer follow-up of existing patients in the ART-CC database. 13 Cumulative probabilities of AIDS and death at up to 5 years from the beginning of ART were provided in the paper that described the update 13 and as an interactive risk calculator on the ART-CC website (www.bris.ac.uk/art-cc/research/calculator/). We investigated, in patients treated for at least 3 years, the prognostic importance, for AIDS and death, of the CD4 cell count and HIV-1 viral load measured at the beginning of ART and at 6 and 36 months later.
14 Although the most recent values of the CD4 cell count and viral load are the most important prognostic factors, changes in the CD4 cell count from 6 to 36 months after the beginning of ART, and the value of the viral load at 6 months, were also prognostic for AIDS. We showed that the incidence of all AIDS-defining events decreased substantially after the beginning of ART, and that the decline was most pronounced for events with a viral aetiology. 15 We found that some patient groups, such as men who have sex with men, experience a greater benefit from ART than do other groups, 16 and that AIDS-related events differed in their importance for subsequent prognosis. 17 In later updates data were collected on non-HIV biomarkers, for example, haemoglobin, liver enzymes and creatinine, and were incorporated into prognostic models. 18 Trends in mortality over time, life expectancy and cause-specific mortality In 2006, after a decade of availability of combination ART, we reported on trends over time in the response to treatment for HIV and the prognosis for treated patients. 19 Standardised mortality rates in HIV-positive individuals were compared with those in countrymatched background populations. 20 Estimates of life expectancy were shown to have increased by some 13 years for patients in whom ART was begun from 2003-2005 as compared with 1996-1999, with an accompanying decline in mortality of nearly 40% in the same period. 21 However, life expectancy in these patients remained well short of that of the general population, and patients treated later in the course of their infection had a shorter life expectancy. From 2006 onward, we collected and classified information about causes of death. Overall, almost 50% of deaths were caused by AIDS. 2 Because rates of death from AIDS declined with the duration of ART, rates of non-AIDS-related death exceeded those of death from AIDS after 4 years of ART. Lifestyle-related causes of death such as suicide, drug overdose, and liver diseases (mainly hepatitis) were the most frequent causes of non-AIDS-related deaths, with the most common non-AIDS-related cancer being lung cancer. Deaths from causes associated with ageing, such as cancers other than lung cancer and cardiovascular disease, will be of increasing importance in treated HIV-positive people over the next decade, and the ART-CC will have the capacity to explore these trends.
When to begin antiretroviral therapy The CD4 cell count below which ART should be begun remains a central issue in the care of HIV-positive individuals. In 2009 we attempted to address this question by combining data from observational cohort studies conducted before and after the era of combination ART, 22 and concluded that deferring treatment until the CD4 cell count was under 350 cells/ml was associated with increased rates of AIDS. International treatment guidelines were amended later in 2009 to account for our own and others' findings, mainly in cohort studies. However only a randomised controlled trial will definitively show whether deferring treatment on the basis of the CD4 cell count will increase the rates of AIDS. Results of the Strategic Timing of Antiretroviral therapy (START) trial 23 are awaited with interest in this regard.
Prognosis for patients infected through injection-drug use
Patients infected with HIV-1 through injection-drug use have worse outcomes after treatment than do those infected sexually. 24 We found that mortality rates of IDUs were twice as high as those of nonIDUs, and that IDUs experienced higher rates than did non-users of infection drugs of almost all causes of death, particularly liver-related deaths and deaths from direct effects of substance abuse. The CD4 cell count predicted death more strongly for non-users of injection drugs than for IDUs, indicating that excess mortality in IDUs was related to factors other than HIV. Excess mortality in IDUs may also relate to suboptimal management of HIV disease in these individuals.
Estimated effects of different antiretroviral drugs on the basis of observational studies and clinical trials
We found evidence that rates of AIDS and death varied according to the drugs included in the initial ART regimen, 19 and that between-regimen differences in rates of short-term virological failure (the outcome most commonly used in clinical trials) do not necessarily translate to longer-term differences in rates of various clinical outcomes. 25 We compared the results of two randomized trials done by the AIDS Clinical Trial Group (ACTG 5095 and ACTG 5142) with those estimated in ART-CC cohorts, which follow patients in routine care. 26 Results for the ART-CC cohorts were comparable with those of the trials conducted in similar settings, and we concluded that the results of clinical trials appear ro be generalisable to routine-care settings in resource-rich countries.
Other topics covered by the Antiretroviral Therapy Cohort Collaborative Collaborative analyses have compared mortality during the first year of ART in resource-limited and high income settings. 9 In the past, similar comparisons of the incidence of tuberculosis were reported. 27, 28 Other questions addressed by the ART-CC include the way in which the effect of prognostic factors at the beginning of ART varies with the duration of treatment, 29 and the effect of baseline CD4 cell counts on the clinical significance of short-term immunologic responses to ART in individuals with virologic suppression. 30 
Current work
We have recently examined the effect of sex, 31 race/ethnicity, and geographical origin 32, 33 on the prognosis in HIV infection and investigated the heterogeneity in mortality rates among cohorts. 3 Ongoing analyses are addressing the durability of first-line ART and the cumulative incidence of and risk factors for different types of changes in regimen and of the interruption of ART. This work will be extended to use methods for causal inference 34 to examine the implications for subsequent mortality of different strategies for switching ART regimens after virological failure. As longer follow-up data become available, we will estimate the prognosis for patients treated for up to 10 years, investigate whether the prognosis in HIV-1 infection becomes stable after an initial response to ART, and investigate the effect of cumulative viral load on specific causes of death. We are also now investigating measures and effects of adherence to ART. What are the main strengths and weaknesses?
The generosity and collaborative spirit of researchers in the contributing cohort studies has been a key strength of ART-CC, which has brought together researchers with clinical, epidemiological and statistical expertise. The ART-CC data base includes large numbers of patients enrolled in diverse cohorts from two continents, so that the results for different cohorts are likely to be generalisable to patients in clinical care in this broad setting. All patients in the ART-CC were ART-naïve when they began treatment, and the results for the Collaboration are therefore relevant to new patients starting combination ART. However, prognostic models are fitted on historic data, and therefore provide trailing indicators of prognosis for new patients starting ART with improved drugs and co-formulations. The large data set of the ART-CC permits examination of prognoses for specific causes of death, but these data are incomplete. So far, it has been possible to classify only 85% of deaths, and there will have been some misclassification because of limitations of available data. There is likely to be some under-ascertainment of deaths, which may result in estimates of mortality rates and life expectancy being over-optimistic. Nevertheless, most of the cohorts in the ART-CC link to death registries, but at intervals that vary from monthly to tri-annually. 3 Because the data are mainly collected as part of routine clinical care, there are issues with the standardisation of definitions and completeness of data. Moreover, not all laboratory, demographic and lifestyle measures are available from all cohorts. Data on important life-style risk factors, such as smoking and substance abuse, which affect mortality and may be highly prevalent in some HIV-positive populations, have not yet been sufficiently widely available for inclusion in prognostic models. Data on adherence to ART are now being collected, but not data on patient physical and psychological symptoms or quality of life measures.
Can I get the data gathered by the Antiretroviral Therapy Collaboration?
The data collected by the ART-CC remain the property of the contributing cohorts, and all analyses of these data must be approved by the ART-CC steering committee. Each cohort has a representative on the steering committee, which also includes patient representatives who provide guidance by asking research questions that are important and relevant to patients. Interested investigators should contact the co-ordinating centre and will be asked to fill in a concept sheet which gives brief details of the proposed study. All concept sheets are discussed by the steering committee, and projects must also be approved by contributing cohorts. We welcome the addition of collaborating cohorts to the ART-CC; eight cohorts have joined since the Collaboration was established in 2000. More information, including details of collaborating centres, is available on the ART-CC website (www.art-cohort-collaboration.org). 
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